Compared to other breast cancer subtypes, TNBC exhibits higher levels of tumor-infiltrating lymphocytes (TILs), PD-L1 expression, and TMB, making it a promising candidate for immune checkpoint inhibitor therapy 28. This evidence concerns the gene CD274 and neoplasm.